Clinical Trials
75 trialsSaltikva for Metastatic Pancreatic Cancer
Salspera LLC
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
PANGEA
UNC Lineberger Comprehensive Cancer Center
NeoPancOne
University Health Network, Toronto
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
PASS-01
University Health Network, Toronto
PREOPANC-5
Amsterdam UMC, location VUmc
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
CIRCULATEIII
UNICANCER
RADIOPAN
Assistance Publique - Hôpitaux de Paris
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
Fox Chase Cancer Center
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
ZSPAC-14
Shanghai Zhongshan Hospital
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
CHAMP
Lund University
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
CENDIFOX
University of Kansas Medical Center
ADVANTAGE
Sahlgrenska University Hospital
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Seoul National University Hospital
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
Oslo University Hospital
LAPIS
Kyntra Bio
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
CONKO-007
University of Erlangen-Nürnberg Medical School
PanC-ASAP
Ability Pharmaceuticals SL
BCC-RAD-13
University of Louisville
FBI-TRAC
King Faisal Specialist Hospital & Research Center
BRAZIL-TNT
Hospital Israelita Albert Einstein
ADAPTA
Fondazione Poliambulanza Istituto Ospedaliero
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
CAPAFOUR
Cantargia AB
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
Instituto de investigación e innovación biomédica de Cádiz
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Zhejiang Cancer Hospital
PROTACT
Silenseed Ltd
PANC-001
Roger Williams Medical Center
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
TIMEPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)